| Company Name: |
NCE Biomedical Co.,Ltd. |
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
|
| | Vicriviroc Malate Basic information |
| Product Name: | Vicriviroc Malate | | Synonyms: | Vicriviroc Malate;1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methylpiperidine malate;CS-599 | | CAS: | 541503-81-5 | | MF: | C32H44F3N5O7 | | MW: | 667.7162696 | | EINECS: | | | Product Categories: | ProteaseInhibitors | | Mol File: | 541503-81-5.mol |  |
| | Vicriviroc Malate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | >18mg/mL in DMSO | | form | Powder | | InChIKey | HQJIGHNTROUVLT-RIAYWLAYSA-N |
| | Vicriviroc Malate Usage And Synthesis |
| Uses | Vicriviroc (SCH 417690) malate is an orally active CCR5 antagonist with the IC50 of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC50 values of 0.91 nM and 16 nM,,respectively. Vicriviroc malate can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer[1][2]. | | Definition | ChEBI: (4,6-Dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone;2-hydroxybutanedioic acid is a member of (trifluoromethyl)benzenes. | | target | CCR5 | | References | [1] Strizki JM, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49(12):4911-4919. DOI:10.1128/AAC.49.12.4911-4919.2005
[2] Bessudo A, et al. Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer. Clin Colorectal Cancer. 2024;23(3):285-294. DOI:10.1016/j.clcc.2024.05.003 |
| | Vicriviroc Malate Preparation Products And Raw materials |
|